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HIGH RATES OF GENITAL TRACT DYSPLASIA IN LONG-TERM SURVIVORS
OF ALLOGENEIC STEM CELL TRANSPLANTATION AND ASSOCIATED RISK
FACTORS
Shanis, D.L.1, Pophali, P.2, Koklanaris, E.2, Savani, B.N.3,
Battiwalla, M.2, Barrett, J.2, Stratton, P.1 1Eunice Kennedy Shriver
NICHD, NIH, Bethesda, MD; 2NHLBI, NIH, Bethesda, MD;
3Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical
Center, Nashville, TN
Background:High rates of cervical dysplasia in women after alloge-
neic stem cell transplantation (allo-HSCT) have been reported, but
risk factors are not well defined.
Objective: To determine rates and risk factors for genital tract dys-
plasia in post-transplant women.
Methods: In a prospective long-term study after allo-HSCT, gyne-
cologic and medical history, and cervical cytology (Pap) were ob-
tained with followup colposcopy and biopsy for abnormal results.
Prior genital tract dysplasia history, time to abnormal Pap/dysplasia,
chronic graft-versus-host-disease (cGVHD), and prolonged immu-
nosuppressive therapy (IST) were assessed for their association
with genital tract dysplasia post-transplant. Chi-squared tests were
used for categoric variables, and logistic regression was used for mul-
tivariate analysis.
Results: All patients received allogeneic transplantation fromHLA-
matched sibling donors with fully myeloablative total body irradia-
tion based conditioning regimens in 55 subjects. The graft source
was marrow in 6 women and ex-vivo T lymphocyte depleted periph-
eral blood stem cells in 54. Of 60 women enrolled, 51 had complete
gyn assessments. Of these 51, 18 (35.3%) had cGVHDrequiring IST
for. 3 years. Seven (13.7%) women had a history of genital dyslasia
prior to allo-HSCT. Of 23 (45.1%) women with abnormal Paps, 15
(29.4%) had biopsy-proven genital dysplasia: 9 cervical, 2 vaginal
and 4 vulvar with other lesions. Chronic GVHD (p 5 1.0), pro-
longed IST for. 3 years (p5 1.0), genitalGVHD (p5 1.0) and gen-
ital GVHD treated by steroids (p 5 0.35) were not associated with
post transplant dysplasia but pretransplant dysplasia was an impor-
tant risk factor. (p 5 0.018) on univariate analyses and subsequently
confirmed by multivariate analysis (Odds ratio 10.3; p 5 0.013).
Conclusion:Women who have undergone allo-HSCT have a high
rate of genital tract dysplasia, especially those with a prior history,
suggestingHPV disease is not newly acquired.While the accelerated
course may be related to immunologic dysfunction our data showed
no relationship to chronic GVHD or to prolonged immunosuppres-
sion. Gynecologic screening prior to transplant and during long
term follow up is an important aspect of transplant care. Our data
supports the use of routine post-transplant HPV vaccination in sus-
ceptible women after allogeneic stem cell transplantation.
Support: NCT ID#: 00106925; NHLBI; PRAE, NICHD; CC,
NIH; Vanderbilt University.213
IMMUNE RESPONSES CONTRIBUTE TO DEPRESSION, FATIGUE, AND
PAIN IN BLOOD AND MARROW TRANSPLANT RECIPIENTS
Costanzo, E.S.1,3, Juckett, M.B.2,3, Nelson, A.M.1,3, Erdmann, A.A.1,3,
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Depression, fatigue, and pain are prevalent and distressing quality
of life concerns for individuals recovering from blood and marrow
transplantation (BMT). Recent research in other cancer populations
suggests inflammatory cytokines can activate central nervous system
pathways, evoking adverse behavioral responses including depressed
mood, fatigue, and pain. We hypothesized that immune responses
also contribute to these symptoms among BMT recipients. Alloge-
neic (n 5 24) and autologous (n 5 68) transplant recipients com-
pleted well-validated measures of depressive symptoms, fatigue,
and pain prior to transplant and 30, 100, and 200 days post-
transplant. Circulating proinflammatory (IL-6, TNFa) and regula-
tory (IL-10) cytokines were measured by ELISA in peripheral bloodplasma at the same points. Subject-level fixed effects and mixed ef-
fects linear regression models were employed to examine relation-
ships between cytokine levels and quality of life assessments.
Results indicated that depression and fatigue were most severe 30
days post-transplant, with allogeneic recipients showing markedly
slower improvement than autologous recipients at later assessments.
Pain was more stable across time. Autologous and allogeneic trans-
plant recipients had comparable cytokine levels prior to transplant,
but allogeneic recipients had significantly higher concentrations
post-transplant (p values\.05), which remained high through Day
200. Among individual patients, changes in IL-6 levels across the as-
sessment points were associated with corresponding changes in de-
pression (t 5 2.0, p 5 .048), fatigue (t 5 2.7, p 5 .008), and pain
(t5 2.0, p5 .048), after covarying for effects of time since transplant.
Similarly, participants with elevated IL-6 levels reportedmore severe
depression (z 5 2.9, p 5 .004), fatigue (z 5 2.9, p 5 .004), and pain
(z 5 3.0 p 5 .003) compared to participants with low/normal IL-6
levels. All models adjusted for graft type and recipient’s age. Similar
relationships were seen for IL-10, but there were no significant ef-
fects for TNFa. Results provide evidence for a novel biobehavioral
pathway by which inflammatory processes associated with condi-
tioning therapy, infection, and/or graft-versus-host disease can con-
tribute to depression, fatigue, and pain. Findings may assist health
care providers in identifying patients most at risk for this constella-
tion of symptoms and suggest novel targets for therapeutic interven-
tions to improve quality of life for individuals recovering fromBMT.214
CERVICAL CYTOLOGY SCREENING IN LONG-TERM SURVIVORS OF ALLO-
GENEIC STEM CELL TRANSPLANTATION WITH GENITAL GRAFT VERSUS
HOST DISEASE
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Background: Cervical cytology testing (Pap) is the screening
method for cervical dysplasia in women, but its utility has not been
studied in women after Allogeneic Stem Cell Transplantation
(SCT) in the context of genital chronic graft-versus-host-disease
(genital cGVHD).
Objective: To examine the clinical findings noted with mildly ab-
normal Pap reports in women post SCT.
Methods: As part of a prospective long-term study after SCT, gyne-
cologic andmedical history, assessment for genital cGVHD, and Pap
were performed. If atypical cells of uncertain significance (ASCUS)
were reported on Pap, high risk (HR) HPV testing was done. Those
with ASCUS +HRHPV underwent colposcopy and biopsy. Patients
with moderate or severe genital cGVHD were treated with vulvar
steroids and followed by gynecology. Chi-square tests and Kaplan-
Meier survival curves were used for univariable and Cox models
for multivariable analyses.
Results: All patients received allogeneic transplantation fromHLA-
matched sibling donors with fully myeloablative total body irradia-
tion based conditioning regimens in 55 subjects. The graft source
was marrow in 6 women and ex-vivo T lymphocyte depleted periph-
eral blood stem cells in 54. Of 60 women enrolled, 51 had complete
gyn assessments. Of these 51, 11(21.6%) had genital cGVHD, with
6(11.8%) requiring vulvar steroids. Of 10 women with ASCUS, 7
were ASCUS -HRHPV. Of the other three, two had biopsy-proven
dysplasia.While both genital cGVHD(p5 0.1) and use of vulvar ste-
roids (p 5 0.07) were weakly associated with a decreased time to
ASCUS Pap in univariable analysis, neither was associated with bi-
opsy-proven dysplasia or time to dysplasia. In multivariable analysis
examining the impact of age, pretransplant dysplasia, cGVHD, gen-
ital GVHD and vulvar steroids, only vulvar steroids (HR 0.2,
p\0.01) and pretransplant dysplasia (HR 0.26, p\0.05) were signif-
icantly associated with the time to abnormal PAP.
Conclusion: ASCUS cytology in women with genital cGVHD re-
quiring vulvar steroids after SCT may represent cytologic changes
of genital cGVHDor portend reactivation ofHPVdisease. Cytology
screening is an important aspect of post transplant gynecology care.
Support:NCT ID:NCT00106925; NHLBI; PRAE, NICHD; CC,
NIH.
